Right decisions in public health are those based on science and expertise: The example of the control of meningococcol disease in Quebec;Santé publique: Le contrôle des maladies mé ningococciques au Québec

Medecine/Sciences

Volumn 19, Issue 10, 2003, Pages 1011-1015

  De Wals, Philippe ^a   Duval, Bernard ^b   De Serres, Gaston ^a   Boulianne, Nicole ^b   Dionne, Marc ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

CANADA; DECISION MAKING; DISEASE CONTROL; ECONOMIC ASPECT; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INFECTION CONTROL; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PROPHYLAXIS; PUBLIC HEALTH; REVIEW; SOCIAL ASPECT; VACCINATION;

NEISSERIA; NEISSERIA MENINGITIDIS;

EID: 0141963999     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200319101011     Document Type: Review

References (24)

1. Sakett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine. How to practice and teach EBM. New York: Churchill Livingstone, 1997: 250 p.
2. Varughese PV, Carter AC. Meningococcal disease in Canada, Surveillance summary to 1987. Can Dis Wkly Rep 1989; 15: 89-96.
3. Ashton FE: Ryan JA, Borczyk A, Caugaant DA, Mancino L, Huang D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991; 29: 2489-93.
4. Lavigne P, Boulianne N, Fortin C, Naccache H, Douville-Fradet M. Meningococcal infections in Quebec, 1991-1992. Can Commun Dis Rep 1992; 18: 113-6.
5. Frasch CE. Meningococcal vaccines: Past, present and future. In: Cartwright K, ed. Meningococcal disease, Chichester: John Wiley and Sons, 1995: 245-83.
6. Taunay AE, Feldman RA, Bastos CO, Galvao PAA, Morais JS, Castro IO. Avalictção do efeito protector de vacina polissacaridica antimenigococica da grupo C, em cricinças de 6 a 36 meses. Rev Inst Adolfo Lutz 1978; 32: 77-82.
7. Direction de la protection de la sonté publique. Bilan de la campagne de vaccination contre les infections à méningocoques. Décembre 1991 à avril 1993. Version initiale. Québec: Ministère de la Santé et des Services sociaux, 1994: 176 p.
8. De Wals P, Dionne M, Douville-Fradet M, Boulianne N, Drapeau J, De Serres G. Impact of a mass immunization campaign against serogroup C meningococcus in the province of Quebec, Canada. Bull WHO 1996; 74: 407-11.
9. Rivest P, Sagot B, Bédard L. Evaluation of the completeness of reporting of invasive meningococcal disease. Can J Publ Health 1999; 90: 250-2.
10. Yergeau A, Alain L, Pless R et al. Adverse events temporally associated with meningococcal vaccines. Can Med Assoc J 1996; 154: 503-7
11. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec (Canada) 1990-1994. Clin Infect Dis 1998; 26: 1159-64.
12. Lebel MH, Tapiero BF, Saintonge F. Immunogenicity of bivalent AC polysaccharide meningococcal vaccine in children aged 6 through 24 months. JAMA 2001; 285: 1578-9.
13. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285: 177-81.
14. De Wals P, Erickson L. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 2002; 20: 2840-4.
15. Hubert B, Caugant DA, Recent changes in meningococcal disease in Europe. Eurosurveillance 1997; 10: 1-4. (http://www.ceses.org/euro surv/v2n10/en15-221.htm).
16. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165 (suppl 1): S49-52.
17. l7. Pollard AJ, Maiden MCJ. Meningococcal vaccines. Methods and protocols. Totowa, New Jersey: Humana Press, 2001: 422 p.
18. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2002; 20: S58-67.
19. Delbecq AL, Van de Ven AH, Gustafson DH. Group techniques for program planning: A guide to nominal group and Delphi processes. Glenview, Illinois: Scott, Foresman and Company, 1975.
20. Comité sur l'immunisation du Québec. Évaluation du coût et des avantages potentiels d'une compagne d'immunisation contre le méningocoque de sérogroupe C au Québec. Québec: Institut de santé publique du Ouébec, Québec, 2001: 1-20. (http://www.inspq.qc.ca).
21. De Wals P, Allard MA, Guindon K, Mayrand L, Simard S, Black R. La vaccination contre le méningocoque est-elle utile? Résultats d'une enquête dans la région de Sherbrooke. Can Commun Dis Rep 2002; 28: 61-3.
22. Comité sur l'immunisation du Québec. Pertinence de l'introduction du vaccin méningococcique dans le celendrier régulier d'immunisation au Québec. Québec: Institut de santé publique du Québec, 2002: 1-16. (http://www.inspq.qc.ca).
23. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81.
24. Erickson LJ, De Wals P, Farand L. Equitable access to vaccination: Immunization program planning in Canada. Report presented to the Division of Immunization, Health Canada, Ottawa, May 22, 2001.